Author: admin

“Bronchial Spasms Market Expected to rise, 2032, DelveInsight”

The Bronchial Spasms market report also offers comprehensive insights into the Bronchial Spasms market size, share, Bronchial Spasms epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Bronchial Spasms market size growth forward.

Some of the key highlights from the Bronchial Spasms Market Insights Report:

• Several key pharmaceutical companies, including GlaxoSmithKline Plc, Merck Sharp & Dohme Corp, AstraZeneca plc, Amphastar Pharmaceuticals, Boehringer Ingelheim International GmbH, Novartis AG, Teva Pharmaceuticals USA, Inc, Viatris Inc, Sunovion Pharmaceuticals Inc., and others, are developing novel products to improve the Bronchial Spasms treatment outlook.

• A 2024 study revealed that benralizumab, a monoclonal antibody targeting eosinophils (a type of white blood cell involved in inflammation), is more effective than traditional steroid tablets in treating eosinophilic exacerbations of asthma and COPD. Administered as a single injection during flare-ups, benralizumab reduced the need for further treatment by 30%, marking the first new treatment approach for asthma attacks in five decades.

• In December 2021, the U.S. Food and Drug Administration (FDA) approved Tezspire as an add-on maintenance treatment for severe asthma in individuals aged 12 and older. Tezspire uniquely targets thymic stromal lymphopoietin, a molecule involved in airway inflammation, and is the first treatment for severe asthma not limited to a specific type. Administered subcutaneously every four weeks by a healthcare professional, Tezspire has demonstrated significant reductions in asthma attacks and associated hospital visits.

• DelveInsight projects that the Bronchial Spasm market will experience steady growth at a favorable CAGR by 2032.

• Major pharmaceutical companies involved in developing treatments for Bronchial Spasm include GlaxoSmithKline, Merck Sharp & Dohme Corp, AstraZeneca plc, Amphastar Pharmaceuticals, Boehringer Ingelheim International GmbH, Novartis AG, Teva Pharmaceuticals USA, Inc., Viatris Inc., Sunovion Pharmaceuticals Inc., among others.

• Notable upcoming therapies expected to enter the market include Fluticasone propionate/salmeterol, HFA MDI, GSK615915A, albuterol, A006, Epinephrine Inhalation Aerosol, and more.

• As per DelveInsight analysis, the Bronchial Spasms market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Bronchial Spasms Market Landscape

Bronchial Spasms Overview

Bronchial spasms, or bronchospasms, are sudden, involuntary contractions of the smooth muscles in the bronchial tubes, causing airway constriction and breathing difficulties. They are a key symptom of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).

Triggers for bronchial spasms include allergens, irritants, cold air, physical activity, infections, and stress. Exposure to these factors can lead to excessive muscle contraction around the airways, resulting in wheezing, coughing, shortness of breath, and chest tightness.

Treatment often involves bronchodilators to relax airway muscles and improve airflow. In more severe cases or asthma attacks, rescue inhalers or nebulizers may be required. Managing underlying conditions and avoiding triggers are also crucial in preventing bronchial spasms.

Do you know the treatment paradigms for different countries? Download our Bronchial Spasms Market Sample Report

Bronchial Spasms Epidemiology Insights

• The World Health Organization (WHO) estimates that approximately 235 million people worldwide are affected by asthma. A lack of awareness about asthma and chronic obstructive pulmonary disease (COPD) not only leads to a rise in cases but also limits the adoption of smart inhalers.

Bronchial Spasms Epidemiology Segmentation

DelveInsight’s Bronchial Spasms market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Bronchial Spasms historical patient pools and forecasted Bronchial Spasms patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Bronchial Spasms Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

• Bronchial Spasms Prevalence

• Age-Specific Bronchial Spasms Prevalence

• Gender-Specific Bronchial Spasms Prevalence

• Diagnosed and Treatable Cases of Bronchial Spasms

Visit for more @ Bronchial Spasms Epidemiological Insights

Bronchial Spasms Market Outlook

Bronchial spasms, or bronchospasms, are sudden contractions of the muscles lining the bronchial tubes, leading to narrowed airways and breathing difficulties. These spasms are characteristic of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).

The market for bronchial spasm treatments is closely linked to the prevalence of asthma and COPD. According to the World Health Organization (WHO), approximately 235 million people worldwide suffer from asthma. The rising incidence of these respiratory conditions has driven demand for effective bronchial spasm therapies.

Bronchodilators remain the primary treatment for bronchial spasms, working to relax airway muscles and improve airflow. The market features both short-acting and long-acting bronchodilators, administered via inhalers or nebulizers.

The bronchial spasm treatment market is expected to grow, driven by increasing respiratory disease prevalence and advancements in therapeutic options. Ongoing research into novel therapies and diagnostic tools is likely to enhance patient outcomes and expand market opportunities.

In summary, the bronchial spasm market is poised for growth, supported by rising demand for effective treatments and continuous innovation in respiratory care.

Bronchial Spasms Key Companies

• GlaxoSmithKline Plc, Merck Sharp & Dohme Corp, AstraZeneca plc, Amphastar Pharmaceuticals, Boehringer Ingelheim International GmbH, Novartis AG, Teva Pharmaceuticals USA, Inc, Viatris Inc, Sunovion Pharmaceuticals Inc., and others

For more information, visit Bronchial Spasms Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Bronchial Spasms Market Report:

• 11 Years Forecast

• 7MM Coverage

• Descriptive overview of Bronchial Spasms, causes, signs and symptoms, diagnosis, treatment

• Comprehensive insight into Bronchial Spasms epidemiology in the 7MM

• Bronchial Spasms marketed and emerging therapies

• Bronchial Spasms companies

• Bronchial Spasms market drivers and barriers

Table of Contents:

1 Bronchial Spasms Market Key Comprehensive Insights

2 Bronchial Spasms Market Report Introduction

3 Competitive Intelligence Analysis for Bronchial Spasms

4 Bronchial Spasms Market Analysis Overview at a Glance

5 Executive Summary of Bronchial Spasms

6 Bronchial Spasms Epidemiology and Market Methodology

7 Bronchial Spasms Epidemiology and Patient Population

8 Bronchial Spasms Patient Journey

9 Bronchial Spasms Treatment Algorithm, Bronchial Spasms Current Treatment, and Medical Practices

10 Key Endpoints in Bronchial Spasms Clinical Trials

11 Bronchial Spasms Marketed Therapies

12 Bronchial Spasms Emerging Therapies

13 Bronchial Spasms: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Bronchial Spasms

16 Bronchial Spasms Market Key Opinion Leaders Reviews

18 Bronchial Spasms Market Drivers

19 Bronchial Spasms Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Bronchial Spasms Epidemiology 2032

DelveInsight’s “Bronchial Spasms – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Bronchial Spasms epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Bronchial Spasms Pipeline 2024

“Bronchial Spasms Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Bronchial Spasms market. A detailed picture of the Bronchial Spasms pipeline landscape is provided, which includes the disease overview and Bronchial Spasms treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bronchial Spasms Market Expected to rise, 2032 | GlaxoSmithKline Plc, Merck Sharp & Dohme Corp, AstraZeneca plc, Amphastar Pharmaceuticals, Boehringer Ingelheim International GmbH, Novartis AG, Teva

“Reactive Airway Disease Market Expected to rise, 2032, DelveInsight”

The Reactive Airway Disease market report also offers comprehensive insights into the Reactive Airway Disease market size, share, Reactive Airway Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Reactive Airway Disease market size growth forward.

Some of the key highlights from the Reactive Airway Disease Market Insights Report:

• Several key pharmaceutical companies, including Sunovion, Vectura Limited, Chiesi Farmaceutici S.P.A, Meda Pharmaceuticals, GSK, Pharmaxis, and others, are developing novel products to improve the Reactive Airway Disease treatment outlook.

• In December 2024, the U.S. Food and Drug Administration (FDA) approved Zepbound (tirzepatide) as the first medication to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound functions by activating intestinal hormone receptors to reduce appetite, leading to weight loss and improved OSA symptoms. Clinical trials showed that participants experienced significant reductions in apnea events and body weight. This approval provides an alternative for patients who struggle with existing treatments like positive airway pressure (PAP) therapy.

• In November 2024, a study published in The Lancet Respiratory Medicine introduced benralizumab as a significant advancement in asthma and Chronic Obstructive Pulmonary Disease (COPD) treatment—the first in 50 years. Benralizumab is a monoclonal antibody that targets eosinophils, white blood cells that contribute to lung inflammation during asthma attacks. The study demonstrated that a single high dose of benralizumab could reduce the need for further treatment by 30% compared to standard steroid tablets. Patients treated with benralizumab experienced better respiratory symptom improvement, fewer treatment failures, and an enhanced quality of life. This development offers a safer and more effective alternative to traditional steroid treatments, potentially administered at home or in general practice settings.

• As per DelveInsight analysis, the Reactive Airway Disease market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Reactive Airway Disease Market Landscape

Reactive Airway Disease Overview

Reactive airway disease refers to a condition with asthma-like symptoms, including coughing, wheezing, chest tightness, and shortness of breath, which occur in response to specific triggers. A thorough evaluation by a healthcare provider is crucial to distinguish it from asthma or other respiratory disorders. Treatment typically focuses on symptom management through medication and avoiding known triggers.

Do you know the treatment paradigms for different countries? Download our Reactive Airway Disease Market Sample Report

Reactive Airway Disease Epidemiology Insights

• The exact prevalence of RAD is difficult to determine due to its non-specific definition. However, it is commonly diagnosed in children under 5 years old who exhibit wheezing or respiratory distress but are too young for formal pulmonary function testing.

• Many cases initially diagnosed as RAD later evolve into asthma, chronic bronchitis, or COPD, particularly in individuals with continued exposure to triggers.

• Studies suggest that up to 30% of children experience wheezing episodes by age 3, though only a portion develop persistent asthma.

Reactive Airway Disease Epidemiology Segmentation

DelveInsight’s Reactive Airway Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Reactive Airway Disease historical patient pools and forecasted Reactive Airway Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Reactive Airway Disease Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

• Reactive Airway Disease Prevalence

• Age-Specific Reactive Airway Disease Prevalence

• Gender-Specific Reactive Airway Disease Prevalence

• Diagnosed and Treatable Cases of Reactive Airway Disease

Visit for more @ Reactive Airway Disease Epidemiological Insights

Reactive Airway Disease Market Outlook

Reactive Airway Disease (RAD) is a term often used to describe asthma-like symptoms such as coughing, wheezing, chest tightness, and shortness of breath triggered by various factors. However, “Reactive Airway Disease” is not a specific medical diagnosis but rather a descriptive term. Consequently, precise market data for RAD is limited. For a comprehensive understanding, we can examine the broader asthma therapeutics market, which encompasses treatments relevant to RAD symptoms.

The pipeline for asthma treatments is robust, with promising candidates in advanced clinical stages. For instance, GSK3511294 (Depemokimab), a long-acting anti-IL-5 monoclonal antibody, offers dosing every 26 weeks, enhancing convenience for patients with severe asthma. Additionally, PT010 by AstraZeneca, a triple-combination inhaler, targets uncontrolled moderate to severe asthma.

Sanofi and Regeneron’s Dupixent received FDA approval as an add-on treatment for adults with chronic obstructive pulmonary disease (COPD) when standard treatments are insufficient. This approval is significant as COPD shares overlapping symptoms with asthma, and Dupixent’s efficacy in improving lung function may influence future asthma treatment paradigms.

While specific market data for Reactive Airway Disease is limited due to its non-specific diagnostic nature, the broader asthma therapeutics market is experiencing significant growth. Advancements in biologic therapies, combination treatments, and innovative drug delivery systems are expected to drive this market forward, offering improved management options for patients with asthma and related respiratory conditions.

Reactive Airway Disease Key Companies

• Sunovion, Vectura Limited, Chiesi Farmaceutici S.P.A, Meda Pharmaceuticals, GSK, Pharmaxis, and others

For more information, visit Reactive Airway Disease Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Reactive Airway Disease Market Report:

• 11 Years Forecast

• 7MM Coverage

• Descriptive overview of Reactive Airway Disease, causes, signs and symptoms, diagnosis, treatment

• Comprehensive insight into Reactive Airway Disease epidemiology in the 7MM

• Reactive Airway Disease marketed and emerging therapies

• Reactive Airway Disease companies

• Reactive Airway Disease market drivers and barriers

Table of Contents:

1 Reactive Airway Disease Market Key Comprehensive Insights

2 Reactive Airway Disease Market Report Introduction

3 Competitive Intelligence Analysis for Reactive Airway Disease

4 Reactive Airway Disease Market Analysis Overview at a Glance

5 Executive Summary of Reactive Airway Disease

6 Reactive Airway Disease Epidemiology and Market Methodology

7 Reactive Airway Disease Epidemiology and Patient Population

8 Reactive Airway Disease Patient Journey

9 Reactive Airway Disease Treatment Algorithm, Reactive Airway Disease Current Treatment, and Medical Practices

10 Key Endpoints in Reactive Airway Disease Clinical Trials

11 Reactive Airway Disease Marketed Therapies

12 Reactive Airway Disease Emerging Therapies

13 Reactive Airway Disease: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Reactive Airway Disease

16 Reactive Airway Disease Market Key Opinion Leaders Reviews

18 Reactive Airway Disease Market Drivers

19 Reactive Airway Disease Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Reactive Airway Disease Epidemiology 2032

DelveInsight’s “Reactive Airway Disease – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Reactive Airway Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Reactive Airway Disease Pipeline 2024

“Reactive Airway Disease Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Reactive Airway Disease market. A detailed picture of the Reactive Airway Disease pipeline landscape is provided, which includes the disease overview and Reactive Airway Disease treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Reactive Airway Disease Market Expected to rise, 2032 | Sunovion, Vectura Limited, Chiesi Farmaceutici S.P.A, Meda Pharmaceuticals, GSK, Pharmaxis, expected to drive market

“Pertussis Market Expected to rise, 2032, DelveInsight”

The Pertussis market report also offers comprehensive insights into the Pertussis market size, share, Pertussis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Pertussis market size growth forward.

Some of the key highlights from the Pertussis Market Insights Report:

• Several key pharmaceutical companies, including Serum Institute of India, LG Chem, ILiAD Biotechnologies, Dynavax Technologies, Tianjin CanSino Biotechnology, Faron Pharmaceuticals, Kymab, BioNet, and others, are developing novel products to improve the Pertussis treatment outlook.

• Pertussis therapies are ADACEL, BOOSTRIX, BPZE1, BK1310/MT-2355, and others.

• The Pertussis market is anticipated to expand as awareness of the disease grows and advancements in treatment and prevention continue to emerge.

• In November 2024, researchers from Tulane University introduced a novel nasal vaccine combining traditional pertussis antigens with an innovative adjuvant called T-vant. This adjuvant enhances the immune response specifically in the respiratory tract. Preclinical studies in mice showed that this vaccine effectively eliminated B. pertussis from both the lungs and nasopharynx three weeks post-infection, whereas traditional intramuscular vaccines did not clear the bacteria from the upper respiratory tract. These findings suggest potential for improved prevention of disease transmission.

• In January 2022, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to BPZE1, a next-generation live-attenuated intranasal pertussis vaccine developed by ILiAD Biotechnologies. BPZE1 aims to address limitations of current vaccines by inducing durable mucosal immunity and reducing nasal colonization, thereby potentially preventing transmission. Clinical trials have shown promising results, including a Phase 2b trial with 300 adult participants demonstrating these benefits.

• As per DelveInsight analysis, the Pertussis market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Pertussis Market Landscape

Pertussis Overview

Pertussis, commonly known as whooping cough, is a highly contagious respiratory infection caused by *Bordetella pertussis*. The term “pertussis” translates to “a violent cough.” The disease progresses through three stages: catarrhal, paroxysmal, and convalescent.

Diagnosing pertussis accurately and promptly can be challenging. Several diagnostic tests are used, including culture, polymerase chain reaction (PCR), paired sera, and single sera. Each test varies in sensitivity and specificity, with paired sera being the most reliable method.

Vaccination remains the most effective way to prevent pertussis. In the United States, two vaccines—DTaP and Tdap—help protect against the disease. Throughout their lifetime, all adolescents and adults should receive at least three documented doses of a tetanus and diphtheria toxoid-containing vaccine (DTaP, DTP, DT, or Td).

Macrolide antibiotics, such as erythromycin, clarithromycin, and azithromycin, are the primary treatment for pertussis and post-exposure prophylaxis (PEP). While erythromycin has historically been recommended, its side effects have led to lower adherence, prompting increased use of newer macrolides.

Do you know the treatment paradigms for different countries? Download our Pertussis Market Sample Report

Pertussis Epidemiology Insights

• In 2022, pertussis vaccination coverage in the United States reached around 19 million. The highest vaccination rate was observed among individuals aged 18 and older, with approximately 5 million receiving the vaccine.

Pertussis Epidemiology Segmentation

DelveInsight’s Pertussis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Pertussis historical patient pools and forecasted Pertussis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Pertussis Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

• Pertussis Prevalence

• Age-Specific Pertussis Prevalence

• Gender-Specific Pertussis Prevalence

• Diagnosed and Treatable Cases of Pertussis

Visit for more @ Pertussis Epidemiological Insights

Pertussis Market Outlook

The most effective way to prevent pertussis is through full immunization. The pertussis vaccine is typically administered alongside diphtheria and tetanus, often combined with poliomyelitis, *Haemophilus influenzae*, and hepatitis B. Three main vaccine formulations are available: DTaP, Tdap, and Td. Before 1980, whole-cell pertussis vaccines (wPV) were widely used, but they were associated with rare but serious side effects, including prolonged crying, febrile seizures, and, in very rare cases, hypotonic-hyporesponsive episodes. To improve safety, acellular pertussis vaccines (aPVs) were later developed. While aPVs have a better safety profile, their efficacy is slightly lower than that of wPVs. Despite this, wPVs remain the most commonly used pertussis vaccine worldwide, mainly due to the high cost of aPVs, which makes them less accessible in low-resource countries.

Treatment for pertussis primarily involves supportive care, including oxygen therapy, suctioning, hydration, and minimizing exposure to respiratory irritants. In severe cases, parenteral nutrition may be required due to the prolonged nature of the illness. Antibiotics are commonly used to treat whooping cough, primarily to reduce bacterial transmission. Erythromycin (40–50 mg/kg per day, up to a maximum of 2 g per day, divided into 2–3 doses) is the first-line treatment. Alternative antibiotics include azithromycin (10 mg/kg on Day 1, followed by 5 mg/kg on Days 2–5) and clarithromycin (15 mg/kg per day in two divided doses).

The U.S. Food and Drug Administration (FDA) has approved 12 combination vaccines to protect against diphtheria and tetanus, including Pentaxim, Infanrix, Pentacel, and Vaxelis. While pertussis vaccination programs have been highly effective across Europe, studies indicate that the disease remains prevalent among middle-aged adults in several European countries.

Pertussis Marketed Drugs

• ADACEL: Sanofi Pasteur

• BOOSTRIX: GlaxosmithKline

Pertussis Emerging Drugs

• BPZE1: ILiAD Biotechnologies

• BK1310/MT-2355: Mitsubishi Tanabe Pharma Corporation

Pertussis Key Companies

• Serum Institute of India, LG Chem, ILiAD Biotechnologies, Dynavax Technologies, Tianjin CanSino Biotechnology, Faron Pharmaceuticals, Kymab, BioNet, and others

For more information, visit Pertussis Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Pertussis Market Report:

• 11 Years Forecast

• 7MM Coverage

• Descriptive overview of Pertussis, causes, signs and symptoms, diagnosis, treatment

• Comprehensive insight into Pertussis epidemiology in the 7MM

• Pertussis marketed and emerging therapies

• Pertussis companies

• Pertussis market drivers and barriers

Table of Contents:

1 Pertussis Market Key Comprehensive Insights

2 Pertussis Market Report Introduction

3 Competitive Intelligence Analysis for Pertussis

4 Pertussis Market Analysis Overview at a Glance

5 Executive Summary of Pertussis

6 Pertussis Epidemiology and Market Methodology

7 Pertussis Epidemiology and Patient Population

8 Pertussis Patient Journey

9 Pertussis Treatment Algorithm, Pertussis Current Treatment, and Medical Practices

10 Key Endpoints in Pertussis Clinical Trials

11 Pertussis Marketed Therapies

12 Pertussis Emerging Therapies

13 Pertussis: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Pertussis

16 Pertussis Market Key Opinion Leaders Reviews

18 Pertussis Market Drivers

19 Pertussis Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Pertussis Epidemiology 2032

DelveInsight’s “Pertussis – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Pertussis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Pertussis Pipeline 2024

“Pertussis Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Pertussis market. A detailed picture of the Pertussis pipeline landscape is provided, which includes the disease overview and Pertussis treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pertussis Market Expected to rise, 2032 | Serum Institute of India, LG Chem, ILiAD Biotechnologies, Dynavax Technologies, Tianjin CanSino Biotechnology, Faron Pharmaceuticals, Kymab, BioNet

“Asphyxia Market Expected to rise, 2032, DelveInsight”

The Asphyxia market report also offers comprehensive insights into the Asphyxia market size, share, Asphyxia epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Asphyxia market size growth forward.

Some of the key highlights from the Asphyxia Market Insights Report:

• Several key pharmaceutical companies, including Pharmazz, Inc., ReAlta Life Sciences, Acer Therapeutics, and others, are developing novel products to improve the Asphyxia treatment outlook.

• In December 2024, the U.S. Food and Drug Administration approved Zepbound for treating moderate to severe OSA in adults with obesity. Zepbound functions by activating receptors of intestinal hormones to reduce appetite and food intake, leading to weight loss and improvement in OSA symptoms. Clinical trials demonstrated a significant reduction in apnea and hypopnea events among participants treated with Zepbound compared to placebo.

• A Phase I clinical study conducted at the Montreal Children’s Hospital explored the use of sildenafil, commonly known as Viagra, to treat newborns suffering from neonatal encephalopathy due to oxygen deprivation during birth. The study found that sildenafil administration is feasible and safe, showing encouraging signs of efficacy in repairing brain injury caused by birth asphyxia. Further research is ongoing to confirm these findings and establish optimal dosing.

• Recent developments in clinical trials for asphyxia have demonstrated significant progress in addressing this critical condition. On August 2, 2023, ReAlta Life Sciences launched a Phase II trial to assess the safety, tolerability, pharmacokinetics, and preliminary effectiveness of RLS-0071 in newborns with hypoxic-ischemic encephalopathy (HIE), also known as birth asphyxia. This randomized, double-blind, placebo-controlled study follows a two-stage, multiple-ascending dose design to explore potential treatments for affected newborns.

• Additionally, a randomized clinical trial conducted by the HEAL Consortium and published in the *New England Journal of Medicine* on January 12, 2022, examined the use of erythropoietin in treating HIE. The study aimed to improve outcomes for infants with birth asphyxia, providing crucial insights for future therapeutic approaches. These advancements highlight ongoing efforts to enhance the understanding and management of asphyxia, ultimately working toward better patient outcomes.

• As per DelveInsight analysis, the Asphyxia market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Asphyxia Market Landscape

Asphyxia Overview

Asphyxia is a condition caused by insufficient oxygen supply, which can lead to organ failure and life-threatening complications. It can result from airway obstruction, drowning, suffocation, or exposure to toxic gases, triggering symptoms such as rapid heart rate, confusion, and loss of consciousness.

There are three main types of asphyxia:

– Mechanical Asphyxia – Caused by airway obstruction or external pressure on the chest.

– Chemical Asphyxia – Results from inhaling toxic substances like carbon monoxide or cyanide, which prevent oxygen utilization.

– Environmental Asphyxia – Occurs in low-oxygen environments, such as confined spaces or high altitudes.

Common symptoms include breathing difficulties, cyanosis (bluish skin), and, in severe cases, unconsciousness or death. Immediate treatment is essential and may involve clearing the airway, providing oxygen, or performing CPR. Early intervention and awareness are crucial in preventing severe outcomes.

Do you know the treatment paradigms for different countries? Download our Asphyxia Market Sample Report

Asphyxia Epidemiology Insights

• Asphyxia, a condition caused by insufficient oxygen supply, affects individuals across various age groups and settings. It is a significant global health concern, particularly in newborns and adults exposed to environmental or occupational hazards.

• Birth asphyxia affects approximately 2 to 3 per 1,000 live births in high-income countries but is significantly higher in low- and middle-income regions, where it contributes to one-quarter of all neonatal deaths.

Asphyxia Epidemiology Segmentation

DelveInsight’s Asphyxia market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Asphyxia historical patient pools and forecasted Asphyxia patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Asphyxia Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

• Asphyxia Prevalence

• Age-Specific Asphyxia Prevalence

• Gender-Specific Asphyxia Prevalence

• Diagnosed and Treatable Cases of Asphyxia

Visit for more @ Asphyxia Epidemiological Insights

Asphyxia Market Outlook

The market for asphyxia-related treatments, particularly focusing on neonatal asphyxia or asphyxia neonatorum, is projected to experience significant growth in the coming years.

The asphyxia market growth is largely attributed to advancements in neuroprotective therapies, including the development of novel therapeutic agents such as neuroprotective drugs, surfactants, and anti-inflammatory agents. These innovations aim to more effectively address the pathophysiology of neonatal asphyxia, targeting critical issues like neuroinflammation and oxygen deprivation-induced brain injury.

Asphyxia Key Companies

• Pharmazz, Inc., ReAlta Life Sciences, Acer Therapeutics, and others

For more information, visit Asphyxia Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Asphyxia Market Report:

• 11 Years Forecast

• 7MM Coverage

• Descriptive overview of Asphyxia, causes, signs and symptoms, diagnosis, treatment

• Comprehensive insight into Asphyxia epidemiology in the 7MM

• Asphyxia marketed and emerging therapies

• Asphyxia companies

• Asphyxia market drivers and barriers

Table of Contents:

1 Asphyxia Market Key Comprehensive Insights

2 Asphyxia Market Report Introduction

3 Competitive Intelligence Analysis for Asphyxia

4 Asphyxia Market Analysis Overview at a Glance

5 Executive Summary of Asphyxia

6 Asphyxia Epidemiology and Market Methodology

7 Asphyxia Epidemiology and Patient Population

8 Asphyxia Patient Journey

9 Asphyxia Treatment Algorithm, Asphyxia Current Treatment, and Medical Practices

10 Key Endpoints in Asphyxia Clinical Trials

11 Asphyxia Marketed Therapies

12 Asphyxia Emerging Therapies

13 Asphyxia: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Asphyxia

16 Asphyxia Market Key Opinion Leaders Reviews

18 Asphyxia Market Drivers

19 Asphyxia Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Asphyxia Epidemiology 2032

DelveInsight’s “Asphyxia – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Asphyxia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Asphyxia Pipeline 2024

“Asphyxia Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Asphyxia market. A detailed picture of the Asphyxia pipeline landscape is provided, which includes the disease overview and Asphyxia treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Asphyxia Market Expected to rise, 2032 | Pharmazz, Inc., ReAlta Life Sciences, Acer Therapeutics, expected to drive market

“Acute Lung Injury Market Expected to rise, 2032, DelveInsight”

The Acute Lung Injury market report also offers comprehensive insights into the Acute Lung Injury market size, share, Acute Lung Injury epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Acute Lung Injury market size growth forward.

Some of the key highlights from the Acute Lung Injury Market Insights Report:

• Several key pharmaceutical companies, including Asklepion Pharmaceuticals, LLC, Edesa Biotech, Direct Biologics, and others, are developing novel products to improve the Acute Lung Injury treatment outlook.

• In December 2024, the U.S. Food and Drug Administration (FDA) approved EB05, a toll-like receptor 4 (TLR4) inhibitor, for the treatment of ALI. TLR4 plays a pivotal role in mediating inflammation associated with ALI, especially in cases triggered by viral infections like SARS-CoV-2 and Influenza. Clinical trials demonstrated that EB05 effectively reduced inflammation and improved lung function in patients with ALI, marking a significant advancement in therapeutic options.

• Recent research has focused on the reactive oxygen species (ROS)/NLRP3 inflammasome pathway, which contributes to inflammation and cell death in ALI. Studies have shown that inhibiting this pathway can protect against lipopolysaccharide (LPS)-induced ALI by reducing ROS/NLRP3-dependent pyroptosis and apoptosis through the Nrf2 signaling pathway. These findings offer promising avenues for developing targeted therapies that address the underlying mechanisms of ALI.

• The Acute Lung Injury market is projected to expand, driven by factors such as the rising incidence of the condition, increased awareness among healthcare professionals, and advancements in both diagnostics and treatment options.

• The emergence of the COVID-19 pandemic led to a substantial increase in cases of ARDS across the 7MM, further contributing to the market’s growth.

• Determining the exact market size remains challenging due to the diverse nature of Acute Lung Injury and its overlap with acute respiratory distress syndrome (ARDS). Nevertheless, the market is anticipated to witness steady growth as the incidence of the condition continues to rise.

• Key players in the Acute Lung Injury market, including Asklepion Pharmaceuticals, LLC, Edesa Biotech, and Direct Biologics, have been actively developing assets within this evolving space. However, the market faces challenges due to the complexity of the condition, the need for personalized treatment strategies, and the high costs associated with research and development.

• Acute lung injury therapies are Neuromuscular Blocking Agents (NMBAs), Inhaled Vasodilators, Corticosteroids, and others.

• As per DelveInsight analysis, the Acute Lung Injury market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Acute Lung Injury Market Landscape

Acute Lung Injury Overview

Acute Lung Injury (ALI) is a condition marked by lung inflammation and damage, leading to compromised gas exchange and respiratory failure. It represents a severe form of lung impairment and can arise from various factors such as infections, trauma, exposure to toxic substances, and sepsis. The American–European Consensus Conference established specific criteria to define ALI and Acute Respiratory Distress Syndrome (ARDS) in both clinical practice and research. The distinction between ALI and ARDS is based on the severity of hypoxemia, measured by the ratio of arterial oxygen partial pressure to inspired oxygen fraction (PaO₂/FiO₂), with ALI exhibiting a less severe degree of hypoxemia compared to ARDS.

Do you know the treatment paradigms for different countries? Download our Acute Lung Injury Market Sample Report

Acute Lung Injury Epidemiology Insights

• Bellani et al. (2016) conducted a multicenter prospective study across 459 ICUs in 50 countries spanning five continents. Their findings revealed that ARDS accounted for 10.4% of all ICU admissions and 23.4% of patients requiring mechanical ventilation. Among ARDS cases, 30.0% were classified as mild, 46.6% as moderate, and 23.4% as severe. The overall unadjusted mortality rates in the ICU and hospital were 35.3% and 40.0%, respectively.

Acute Lung Injury Epidemiology Segmentation

DelveInsight’s Acute Lung Injury market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Acute Lung Injury historical patient pools and forecasted Acute Lung Injury patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Acute Lung Injury Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

• Acute Lung Injury Prevalence

• Age-Specific Acute Lung Injury Prevalence

• Gender-Specific Acute Lung Injury Prevalence

• Diagnosed and Treatable Cases of Acute Lung Injury

Visit for more @ Acute Lung Injury Epidemiological Insights

Acute Lung Injury Market Outlook

The current treatment strategy for ALI focuses on supportive care, addressing the underlying cause (e.g., infections or sepsis), and managing complications. This includes administering antibiotics, corticosteroids, and anti-inflammatory medications. However, existing therapies primarily target inflammation and do not directly restore lung function, highlighting a significant need for new treatments.

Several randomized controlled trials have explored pharmacological interventions for ALI, but no definitive treatment has been successful. Research is ongoing into mechanisms such as inhibiting the ROS/NLRP3 pathway, which may protect against ALI by preventing inflammation-induced cell death. EB05, a toll-like receptor 4 (TLR4) inhibitor, has gained attention for its potential role in treating ALI, particularly in cases triggered by viral infections like SARS-CoV-2 and Influenza.

Emerging therapies are investigating novel pharmacological agents that target specific inflammatory pathways, including anti-inflammatory cytokines, antioxidants, and immunomodulators. Additionally, advancements in precision medicine and personalized approaches may lead to more effective, tailored treatments for ALI in the future.

Acute Lung Injury Emerging Drugs

• L-citrulline: Asklepion Pharmaceuticals, LLC

• EB05: Edesa Biotech

Acute Lung Injury Key Companies

• Asklepion Pharmaceuticals, LLC, Edesa Biotech, Direct Biologics, and others

For more information, visit Acute Lung Injury Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Acute Lung Injury Market Report:

• 11 Years Forecast

• 7MM Coverage

• Descriptive overview of Acute Lung Injury, causes, signs and symptoms, diagnosis, treatment

• Comprehensive insight into Acute Lung Injury epidemiology in the 7MM

• Acute Lung Injury marketed and emerging therapies

• Acute Lung Injury companies

• Acute Lung Injury market drivers and barriers

Table of Contents:

1 Acute Lung Injury Market Key Comprehensive Insights

2 Acute Lung Injury Market Report Introduction

3 Competitive Intelligence Analysis for Acute Lung Injury

4 Acute Lung Injury Market Analysis Overview at a Glance

5 Executive Summary of Acute Lung Injury

6 Acute Lung Injury Epidemiology and Market Methodology

7 Acute Lung Injury Epidemiology and Patient Population

8 Acute Lung Injury Patient Journey

9 Acute Lung Injury Treatment Algorithm, Acute Lung Injury Current Treatment, and Medical Practices

10 Key Endpoints in Acute Lung Injury Clinical Trials

11 Acute Lung Injury Marketed Therapies

12 Acute Lung Injury Emerging Therapies

13 Acute Lung Injury: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Acute Lung Injury

16 Acute Lung Injury Market Key Opinion Leaders Reviews

18 Acute Lung Injury Market Drivers

19 Acute Lung Injury Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Acute Lung Injury Epidemiology 2032

DelveInsight’s “Acute Lung Injury – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Acute Lung Injury epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Acute Lung Injury Pipeline 2024

“Acute Lung Injury Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acute Lung Injury market. A detailed picture of the Acute Lung Injury pipeline landscape is provided, which includes the disease overview and Acute Lung Injury treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Lung Injury Market Expected to rise, 2032 | Asklepion Pharmaceuticals, LLC, Edesa Biotech, Direct Biologics, expected to drive market